Latest Insider Transactions at Scholar Rock Holding Corp (SRRK)
This section provides a real-time view of insider transactions for Scholar Rock Holding Corp (SRRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Scholar Rock Holding Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Scholar Rock Holding Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2022
|
Yung H. Chyung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+12.67%
|
-
|
|
Feb 14
2022
|
Nagesh K. Mahanthappa Interim CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 14
2022
|
Gregory John Carven Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+29.73%
|
-
|
|
Feb 14
2022
|
Junlin Ho GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+33.31%
|
-
|
|
Feb 14
2022
|
Edward H Myles COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
57,500
+41.98%
|
-
|
|
Jan 18
2022
|
Gregory John Carven Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,137
-2.33%
|
$21,603
$19.46 P/Share
|
|
Jan 18
2022
|
Yung H. Chyung Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,421
-0.64%
|
$26,999
$19.46 P/Share
|
|
Jan 18
2022
|
Edward H Myles COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,178
-9.02%
|
$41,382
$19.46 P/Share
|
|
Jan 18
2022
|
Junlin Ho GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
1,042
-2.7%
|
$19,798
$19.46 P/Share
|
|
Nov 17
2021
|
Amir Nashat |
BUY
Other acquisition or disposition
|
Direct |
7,441
+25.14%
|
-
|
|
Nov 17
2021
|
Amir Nashat |
SELL
Other acquisition or disposition
|
Indirect |
339,098
-55.0%
|
-
|
|
Nov 17
2021
|
Amir Nashat |
BUY
Other acquisition or disposition
|
Indirect |
56,009
+50.0%
|
-
|
|
Nov 15
2021
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
4,879
-16.81%
|
$170,765
$35.05 P/Share
|
|
Nov 15
2021
|
Edward H Myles COO & CFO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
4,879
+14.39%
|
-
|
|
Nov 12
2021
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
49,848
-67.36%
|
$1,744,680
$35.12 P/Share
|
|
Nov 12
2021
|
Edward H Myles COO & CFO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
49,848
+40.25%
|
-
|
|
Nov 11
2021
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
23,574
-49.4%
|
$825,090
$35.2 P/Share
|
|
Nov 11
2021
|
Edward H Myles COO & CFO |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
23,574
+33.06%
|
-
|
|
Oct 01
2021
|
Jeffrey S. Flier |
SELL
Open market or private sale
|
Indirect |
6,000
-21.22%
|
$180,000
$30.89 P/Share
|
|
Sep 20
2021
|
Jeffrey S. Flier |
SELL
Open market or private sale
|
Direct |
500
-5.26%
|
$17,000
$34.09 P/Share
|
|
Jul 26
2021
|
Jeffrey S. Flier |
SELL
Open market or private sale
|
Indirect |
6,000
-9.17%
|
$186,000
$31.66 P/Share
|
|
Mar 15
2021
|
Michael Gilman |
SELL
Open market or private sale
|
Direct |
4,696
-11.14%
|
$305,240
$65.59 P/Share
|
|
Feb 08
2021
|
Michael Gilman |
SELL
Open market or private sale
|
Direct |
1,804
-4.1%
|
$117,260
$65.06 P/Share
|
|
Feb 01
2021
|
Stuart A Kingsley President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+50.0%
|
-
|
|
Feb 01
2021
|
Edward H Myles COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
24,150
+50.0%
|
-
|
|
Feb 01
2021
|
Yung H. Chyung Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,750
+50.0%
|
-
|
|
Feb 01
2021
|
Gregory John Carven Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,600
+50.0%
|
-
|
|
Jan 27
2021
|
Gregory John Carven Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
19,100
-15.72%
|
$1,069,600
$56.79 P/Share
|
|
Jan 27
2021
|
Gregory John Carven Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,619
+7.41%
|
$99,285
$15.11 P/Share
|
|
Jan 26
2021
|
Gregory John Carven Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
36,774
-10.9%
|
$2,169,666
$59.71 P/Share
|
|
Jan 26
2021
|
Gregory John Carven Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,900
+13.12%
|
$339,900
$11.63 P/Share
|
|
Jan 26
2021
|
Michael Gilman |
SELL
Open market or private sale
|
Direct |
3,501
-2.52%
|
$203,058
$58.97 P/Share
|
|
Jan 26
2021
|
Michael Gilman |
BUY
Exercise of conversion of derivative security
|
Direct |
3,501
+3.61%
|
$17,505
$5.77 P/Share
|
|
May 29
2018
|
Artal International S.C.A. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
450,000
+50.0%
|
$6,300,000
$14.0 P/Share
|
|
May 29
2018
|
Artal International S.C.A. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,946,040
+50.0%
|
-
|